Dossier licensing

  • over 50 dossiers available and
  • 200 generic projects in pipeline
  • more than 150 highly qualified scientists in R&D high potency, cytotoxics, softgels, hormones & IR/ ER oral dosage forms
  • sites approved by US, EU and JP health authorities
Commercial network
35
Pipeline ANDA'S
75

CTD DOSSIERS
  

Recently Available Dossiers

Lenalidomide capsules: 2.5, 5, 7.5, 10, 15, 20 and 25 mg

Gefitinib tablets: 250 mg

Vinorelbine capsules: 20, 30 and 80 mg

Trimetazidine ER tablets: 35 mg

Ulipristal tablets: 5 mg

Coming Soon

Pazopanib tablets: 200 and 400 mg

Sunitinib capsules: 12.5, 25, 37.5 and 50 mg

Enzalutamide capsules: 40 mg

Rivaroxaban: 2.5, 10, 15 and 20 mg tablets

Ticagrelor: 60 and 90 mg tablets

Nilotinib: 150 and 200 mg capsules

Sorafenib: 200 mg tablets

Betahistine: 8, 16 and 24 mg tablets

Rosuvastatin: 5, 10, 20 and 40 mg tablets

Bazedoxifene: 20 mg tablets

Connect with us

Connect with our Global business development team by sending a message to businessdevelopment@alvogen.com


None of the products listed above are available for countries where the offer and/or supply of the product could be deemed an infringement of the IP rights of third parties.